Clinical

Dataset Information

0

A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer


ABSTRACT: Primary objectives: To evaluate the objective tumour response in patients with advanced colorectal cancer when treated with CP-4055 for infusion D1-5/4w. Primary endpoints: Tumour response defined as Complete Response (CR) and/or Partial Response (PR), characterized by measuring the target lesions, and according to the RECIST criteria.The Response Rate (= PR + CR) will be estimated and a 95 % confidence interval calculated.

DISEASE(S): A Phase Ii Clinical Study Of Elacyt As Second Line Therapy In Patients With Advanced Colorectal Cancer

PROVIDER: 2521306 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2014-02-27 | GSE46715 | GEO
2015-12-31 | E-GEOD-68871 | biostudies-arrayexpress
2014-02-27 | E-GEOD-46715 | biostudies-arrayexpress
2014-08-12 | E-GEOD-48664 | biostudies-arrayexpress
| 2518286 | ecrin-mdr-crc
| 2538235 | ecrin-mdr-crc
| 2687328 | ecrin-mdr-crc
2020-09-16 | ST001527 | MetabolomicsWorkbench
2010-03-09 | E-GEOD-19293 | biostudies-arrayexpress
2023-06-28 | GSE196224 | GEO